Recently, immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) and the programmed cell death‐1 (PD‐1)/programmed cell death‐ligand‐1 (PD‐L1) pathway were developed and showed a robust and durable responses in patients with various cancers,7, 8 including BLCA.9 This evidence concerns the gene CD274 and bladder transitional cell carcinoma.